Anthony P. Fernandez, MD, PhD; Amy S. Paller, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Novartis.
Psoriasis frequently presents differently in pediatric patients than in their adult counterparts. Accurate and timely diagnosis is imperative for implementation of effective treatment that can not only counteract the skin manifestations, but also help ameliorate the psychological and systemic effects of psoriasis. Since there are now 4 US Food and Drug Administration (FDA)-approved target biologic pharmacotherapeutics available for pediatric patients with psoriasis, it is critical that providers understand the indications and clinical trial data for these agents. In this activity, expert faculty discuss a pediatric patient who has been misdiagnosed with seborrheic dermatitis, but actually has moderate to severe psoriasis.
The educational design of this activity addresses the needs of dermatologists, pediatric dermatologists, pediatricians, and other clinicians involved in the treatment of pediatric patients with psoriasis.
Anthony P. Fernandez, MD, PhD
Assistant Professor of Clinical Medicine, CCLCM
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics (Dermatology)
Feinberg School of Medicine
After completing this activity, the participant should be better able to:
- Comprehensively assess patients with psoriasis for potential clinical manifestations, multisystem effects, and patient-reported outcomes
- Discuss the clinical profiles and trial results for current and emerging targeted treatment options for psoriasis
- Construct treatment regimens for patients with moderate to severe psoriasis based on disease presentation, comorbidities, therapeutic responses, and shared decision making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 100% on the posttest, and complete the program evaluation.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Anthony P. Fernandez, MD, PhD:
Consultant: AbbVie Inc., Bristol Myers Squibb Company, UCB, Inc.
Contracted research: AbbVie Inc., Alexion Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc.
Honoraria: AbbVie Inc., Bristol Myers Squibb Company, Kyowa Kirin, inc., UCB, Inc.
Speakers Bureau: AbbVie Inc., Kyowa Kirin, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation
Amy S. Paller, MD:
Consultant: Aegerion Pharmaceuticals Inc., Azitra, Inc., BioCryst Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Castle Creek Biosciences, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Krystal Biotech, Inc., LEO Pharma A/S, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi/Genzyme, Seanergy Dermatology Ltd., TWi Biotechnology, Inc., UCB, Inc.
DSMB: AbbVie Inc., Abeona Therapeutics Inc., Catawba Research, Galderma Laboratories, L.P., INMED
Contracted research: AbbVie Inc., Dermavant Sciences, Inc., Eli Lilly and Company, Incyte Corporation, Janssen Pharmaceuticals, Inc., Krystal Biotech, Inc, UCB, Inc.
The Global and Integritas Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.25
credit type CME/ANCC
type Webcast Series
Focus on Psoriasis